Skip to main
ANIK
ANIK logo

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics Inc. has demonstrated strong financial performance, with management reporting that its Integrity product achieved sequential revenue growth and is projected to exhibit over 100% growth from 2024 to 2025. Additionally, the company experienced a significant increase in international osteoarthritis (OA) pain revenue, rising by 21% year-over-year, further enhancing its growth trajectory. The regenerative solutions business also performed well, showing an impressive 41% growth in the quarter, underscoring the company's commitment to innovative therapies in the orthopedic space.

Bears say

Anika Therapeutics Inc reported a revenue decline of 5.9% to $27.8 million, reflecting ongoing challenges in its revenue generation, with previous reports indicating an 8.2% decrease compared to the prior year, highlighting a consistent downward trend. The company's disappointing gross margin of 56%, falling short of the estimated 58%, is attributed to production yield issues that have persisted, further straining its financial performance. Additionally, international revenue from osteoarthritis pain management saw a significant 10% decline, exacerbating concerns over order timing and recurring production problems which contribute to a negative outlook for the stock.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.